SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res. 2005; 11: 25102517.
  • 2
    Kallio JP, Hirvikoski P, Helin H, et al. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J Urol. 2004; 172(6 Pt 1): 21582161.
  • 3
    Lam JS, Shvarts O, Said JW, et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005; 103: 25172525.
  • 4
    Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004; 171(6 Pt 1): 24612466.
  • 5
    Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133: 17101715.
  • 6
    Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol. 1992; 168: 8586.
  • 7
    Cheville JC, Zincke H, Lohse CM, et al. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer. 2002; 94: 21802184.
  • 8
    Lehmann J, Retz M, Nurnberg N, et al. The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma. Cancer. 2004; 101: 15521562.
  • 9
    Kramer BA, Gao X, Davis M, Hall M, Holzbeierlein J, Tawfik O. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J Am Coll Surg. 2005; 201: 565570.
  • 10
    Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int. 2004; 93: 10871093.
  • 11
    Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer. 2005; 104: 511520.
  • 12
    Swanson DA, Rothenberg HJ, Boynton AL, et al. Future prognostic factors for renal cell carcinoma: Workgroup No. 5. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997; 80: 997998.
  • 13
    Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003; 27: 612624.
  • 14
    Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol. 2005; 173: 18891892.
  • 15
    Ljungberg B, Alamdari FI, Stenling R, Roos G. Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol. 1999; 36: 565569.
  • 16
    Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
  • 17
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002; 168: 23952400.
  • 18
    Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353: 24772490.
  • 19
    Kunkle DA, Haas NB, Uzzo RG. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep. 2007; 8: 1930.
  • 20
    Tollefson MK, Takahashi N, Leibovich BC. Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma. Curr Urol Rep. 2007; 8: 3843.
  • 21
    Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003; 170(6 Pt 1): 22252232.
  • 22
    Ficarra V, Martignoni G, Lohse C, et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. J Urol. 2006; 175: 12351239.
  • 23
    Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol. 2005; 174: 17591763; discussion 1763.
  • 24
    Cheville NF. Consequences of acute cell injury: necrosis, recovery and hypertrophy. In: ChevilleNF, ed. Ultrastructural Pathology: An Introduction to Interpretation. Ames: Iowa State University Press; 1994: 81103.
  • 25
    Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31: 1320.
  • 26
    Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993; 123: 513522.
  • 27
    Endl E, Gerdes J. Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol. 2000; 182: 371380.
  • 28
    MacCallum DE, Hall PA. Biochemical characterization of pKi67 with the identification of a mitotic-specific form associated with hyperphosphorylation and altered DNA binding. Exp Cell Res. 10 1999; 252: 186198.
  • 29
    Scholzen T, Endl E, Wohlenberg C, et al. The Ki-67 protein interacts with members of the heterochromatin protein 1 (HP1) family: a potential role in the regulation of higher-order chromatin structure. J Pathol. 2002; 196: 135144.
  • 30
    Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000; 257: 231237.
  • 31
    Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23: 72127220.
  • 32
    Donskov F, Marcussen N, Hokland M, Fisker R, Madsen HH, von der Maase H. In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma. Br J Cancer. 2004; 90: 626631.